Roche Backs 2021 Views After 1Q Sales Fall Slightly
By Olivia Bugault
Roche Holding AG said Wednesday that sales slightly decreased in
its first quarter, while it confirmed its outlook for the year.
The Swiss pharmaceutical major posted sales of 14.93 billion
Swiss francs ($16.30 billion), down from CHF15.14 billion a year
earlier. At constant exchange rate, sales increased 3%, it
An analysts' consensus provided by FactSet had sales at CHF15.01
Sales at its pharmaceuticals division--its largest
business--fell to CHF10.6 billion from CHF12.26 billion, while it
rose 55% at constant exchange rate at its diagnostic division, it
The decline in sales at its pharmaceuticals business is mainly
because of the coronavirus pandemic and the competition of
biosimilars, Roche said. "The impact of biosimilars on sales of the
established cancer medicines MabThera/Rituxan, Avastin and
Herceptin remained significant (combined sales reduction of CHF1.6
billion), especially in the U.S.," it said.
Roche confirmed its 2021 outlook that includes expected sales
growth in the low-to-mid-single-digit range at constant exchange
Write to Olivia Bugault at email@example.com
(END) Dow Jones Newswires
April 21, 2021 01:39 ET (05:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.